Hugh M. Cole - 01 Feb 2022 Form 4/A - Amendment Insider Report for Jounce Therapeutics, Inc.

Role
Chief Business Officer
Signature
/s/ Caroline Gammill, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
17 Mar 2022, 20:50:55 UTC
Date Of Original Report
03 Feb 2022
Previous filing
11 Jan 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 01 Feb 2022 Common Stock 85,000 $7.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Option will vest (i) as to 55,000 shares of the Stock Option, quarterly in 16 equal installments following January 1, 2022 and (ii) as to 30,000 shares of the Stock Option, on January 1, 2023.

Remarks:

This Form 4/A amends the Form 4 filed on February 3, 2022 to correct the vesting schedule of the Stock Option granted to the Reporting Person.